Form 4: Teva Pharmaceutical Industries Executive Receives Stock Grant

Christine Fox, EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries, was granted 81,845 restricted share units on March 4, 2024.

Summary

• Christine Fox, an executive at Teva Pharmaceutical Industries, received a grant of 81,845 restricted share units on March 4, 2024.
• These restricted share units will vest in installments over four years, starting on March 4, 2025.
• Each restricted share unit represents the right to receive one ordinary share or its cash value.
• The ordinary shares may be represented by American Depositary Shares (ADS).
• The price of the derivative security is $0.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of restricted share units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Companies like Pfizer, Johnson & Johnson, and Merck also use stock grants as part of their executive compensation packages.
• The vesting schedule and the number of shares granted are generally in line with industry practices for executives at similar levels.

Stakeholder Impact

• Shareholders may view the stock grant as a positive sign, aligning executive interests with company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates